News|Articles|May 28, 2026

Policy Fatigue: The Future of Patient Access in Pharma

Key Takeaways

Understand how “policy fatigue” is shaping access, affordability, and coverage decisions
Identify the key disconnects between formulary coverage and real patient access
Examine how organizations are adapting access, pricing, and patient support in a rapidly evolving environment

Across the pharmaceutical industry, coverage does not inherently mean access. As a result, the industry must overcome "policy fatigue" by rethinking access strategies, pricing models, and organizational integration to bridge the critical gap between product coverage and real-world patient access.

Q&A With Dane Schroeder from BGB Group on Policy Fatigue and Patient Access vs Real-World Coverage in Pharma

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Policy Fatigue: The Future of Patient Access in Pharma

Key Takeaways

Related Content

Overcome Barriers to Specialty Medication Adherence

One Connection, Endless Impact: Improving Patient Medication Access

Trending on PharmExec

Nuvation Bio’s Approach to Building a Compelling Narrative

Insilico Medicine Enters $2.5 Billion Alliance with Bora Pharmaceuticals

Steer Bio Targets Lymphedema with Regenerative Cell Therapy Platform

Nuvation Bio’s Global Strategy

FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease